Xencor Inc (XNCR): Capital Expenditures
$3.15M
Year ended 2025-12-31
$2.47M
Trailing 12 months to 2026-06-30
-56.6%
3-year compound annual growth
-21.5%
5-year compound annual growth
+5.0%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.15M | -48.3% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $6.10M | -67.0% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $18.45M | -52.1% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $38.49M | +189.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $13.30M | +26.2% | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | $10.54M | +43.3% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $7.35M | +2.0% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $7.21M | +35.8% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $5.31M | +252.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $1.51M | -21.9% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $1.93M | +147.4% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $780.0K | +473.5% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $136.0K | +231.7% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $41.0K | n/a | 2015-02-23, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | $3.15M | -48.3% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $13.41M | -27.1% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $0 | -100.0% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $1.52M | -23.6% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $1.91M | -48.4% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗